Trials / Active Not Recruiting
Active Not RecruitingNCT03179930
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of the study drugs called Pembrolizumab and Entinostat when used in combination to treat lymphoma. This combination could shrink the lymphoma but it could also cause side effects. Researchers also hope to learn whether adding entinostat to pembrolizumab can be more effective for patients with lymphoma than either drug alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Entinostat | All patients will receive entinostat 5-7 mg PO as per the dosing regimen at the on D1, D8, and D15 |
| DRUG | Pembrolizumab | pembrolizumab 200 mg IV on D1 |
Timeline
- Start date
- 2017-06-07
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2017-06-07
- Last updated
- 2025-07-23
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03179930. Inclusion in this directory is not an endorsement.